Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Intellia and ReCode join forces on cystic fibrosis gene therapy

EditorEmilio Ghigini
Published 2024-02-15, 07:48 a/m
Updated 2024-02-15, 07:48 a/m
© Reuters.

CAMBRIDGE, Mass. & MENLO PARK, Calif. - Intellia Therapeutics, Inc. (NASDAQ:NTLA), known for its CRISPR-based gene editing technologies, and ReCode Therapeutics, a genetic medicines company, have announced a partnership to develop genomic medicines for cystic fibrosis (CF). The collaboration aims to harness Intellia's gene editing platform and ReCode's proprietary lipid nanoparticle delivery system to target CFTR gene mutations responsible for CF.

The strategic alliance is set to focus on creating treatments for CF patients with limited or no existing therapeutic options. Intellia will lead the design of the gene editing components, while ReCode will oversee preclinical and clinical development, along with global commercialization for certain programs. Intellia is eligible for development and commercial milestone payments and royalties on sales, with an option to take charge of U.S. commercialization for some programs.

John Leonard, M.D., CEO of Intellia, expressed enthusiasm for the potential impact on CF patients' lives, emphasizing the importance of extending the reach of their CRISPR platform beyond liver targets. ReCode's CEO, Shehnaaz Suliman, M.D., echoed this sentiment, highlighting the collaboration's potential to accelerate the delivery of next-generation gene editing therapeutics to patients.

CF is a life-threatening genetic disorder marked by the buildup of thick mucus in the lungs and other organs, which can cause severe respiratory and digestive issues. Intellia's in vivo programs focus on editing genes within the body, while their ex vivo efforts involve engineering cells outside the body for cancer and autoimmune disease treatments.

ReCode's SORT lipid nanoparticle platform is designed for precise delivery of genetic medicines to specific organs and tissues. The company is advancing its pipeline, which includes mRNA-based therapies for primary ciliary dyskinesia and a subset of CF patients unresponsive to current treatments.

This collaboration represents a significant step in the development of gene therapies for CF, a condition with a critical need for more effective treatments. The partnership's success will depend on the integration of Intellia's gene editing technology with ReCode's delivery system, aiming to bring transformative solutions to the CF community.

The information in this article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.